An interventional study of acupuncture and sham acupuncture in Atopic Dermatitis, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Not applicable, Interventional, and Treatment
This study used a multicentre parallel three-armed randomised sham-controlled clinical trial methodology in order to objectively and normatively assess the efficacy of acupuncture on Quchi the Sea of Blood the Foot Sanli and the Sanyinjiao in the treatment of moderate-to-severe atopic dermatitis so as to obtain high-level evidence-based medical evidence.
This study adopts a multi-centre, parallel, three-armed, randomized, sham-controlled clinical trial method, and will be conducted at Yueyang Hospital of Integrative Medicine affiliated with Shanghai University of Traditional Chinese Medicine, Huashan Hospital affiliated with Fudan University, and Seventh People's Hospital affiliated with Shanghai University of Traditional Chinese Medicine. Eligible patients with moderate-to-severe AD will be divided into three groups using stratified block randomisation in the ratio of 2:2:1: the acupuncture group, the sham-acupuncture group and the waitlisted control group. The total observation period is 9 weeks, including a 1-week introduction period, a 4-week treatment period and a 4-week follow-up period.
1,443 studies on the registry are indexed under Dermatitis, Atopic; 253 are open to participants now.
This study's planned enrollment of 110 is above the median of 83 across 1,143 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Shanghai Yueyang Integrated Medicine Hospital is the lead sponsor of 38 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the diagnostic criteria for moderate to severe atopic dermatitis;
Exclusion Criteria:
Patients who are in the acute onset of the disease and have erosions exudates and secondary infections;
Patients who have participated in other clinical studies in the past 3 months or are participating in other clinical studies; ③ Patients with severe haematological diseases (e.g. platelet count \<50×109 /L) and other serious diseases that may affect operation and efficacy;
Current systematic use of glucocorticosteroids discontinued for less than 7 days; immunosuppressants (cyclosporine methotrexate tretinoin etc.) discontinued for less than 1 month; dulprevirizumab discontinued for less than 1 month JAK inhibitors discontinued for less than 2 weeks;
Device: acupuncture
Device: sham acupuncture
Subjects in the acupuncture group received traditional acupuncture. The needles were inserted to induce a sense of 'getting qi' and left in place for 30 minutes.
Sterile disposable retractable needles and a fake placebo acupuncture device are used for sham acupuncture. The acupuncturist attached the base of the sham acupuncture device to the acupoints, and then inserted sterile disposable blunt-tipped retractable needles into the tubes; when the blunt tips touched the skin, the needles retracted into the handles, and there was no sensation of getting qi.
SCORing atopic dermatitis（SCORAD）
SCORAD range of 0 \~ 103 points.The condition is classified as mild, moderate or severe according to the score, with the higher the score, the more severe the condition.
Time frame: This indicator will be measured at baseline day 1 (V2), day 27 ± 1 (V9), and day 56 ± 3 (V10).
Patient Oriented Eczema Measure (POEM)
Patients themselves assessed the frequency and severity of 7 symptoms occurring in the past 1 week, with each entry on a 5-point scale corresponding to a score of 0, 1, 2, 3, and 4. Scores ranged from 0 \~ 28, with higher scores indicating greater severity.
Time frame: This indicator will be measured at baseline day 1 (V2), day 27 ± 1 (V9), and day 56 ± 3 (V10).
Dermatology Life Quality Index（DLQI）
The questionnaire contains 10 questions. Scores range from 0 to 30, with higher scores indicating a greater impact on quality of life.
Time frame: This indicator will be measured at baseline day 1 (V2), day 27 ± 1 (V9), and day 56 ± 3 (V10).
Peak Pruritus Numerical Rating Scale（PP-NRS）
The PP-NRS is a patient self-report, with a score of 0 for no itching and 10 for the worst itching imaginable, with the patient scoring the worst itching experienced in the last 24 h. The PP-NRS is a patient self-report, with a score of 0 for no itching and 10 for the worst itching imaginable.
Time frame: This indicator will be measured at baseline day 1 (V2), day 27 ± 1 (V9), and day 56 ± 3 (V10).
Skin Peripheral sympathetic nerve activity (SKNA)
Measured with neuECG, SKNA in µV
Time frame: This indicator will be measured at baseline day 1 (V2), day 27 ± 1 (V9).
Serum total IgE
Time frame: This indicator will be measured at baseline day 1 (V2), day 27 ± 1 (V9).
Peripheral blood serum cytokines（IL-4,IL-13,IL-31,IL-33,INF-α）
Time frame: This indicator will be measured at baseline day 1 (V2), day 27 ± 1 (V9).
No study locations are listed for this record.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Yueyang Integrated Medicine Hospital